西村 潤一 にしむら じゅんいち 先生

来歴等

略歴

1999年 大阪大学医学部附属病院 医員
2000年 大阪府立病院 消化器一般外科
2002年 八尾徳洲会総合病院 心臓血管外科
2004年 大阪大学医学部附属病院 医員
2005年 九州大学 生体防御医学研究所 研究員
2006年 大阪大学大学院 医学研究科 博士課程
2007年 大阪大学医学部附属病院 医員
2009年 大阪労災病院 外科 医長
2010年 大阪大学医学部附属病院 助教
2017年 大阪国際がんセンター 消化器外科 副部長

論文

• 1. Adjuvant Chemotherapy after Neoadjuvant Chemotherapy and Long-term Outcomes of CAPOX Plus Bevacizumab Followed by TME for High-risk Localized Rectal Cancer. J Anus Rectum Colon 2020;4(3):108-113.

  Nishimura J, Hasegawa J, Noura S, Ikeda K, Yasui M, Komori T, et al.

• 2. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial. Eur J Cancer 2015;51(10):1274-82.

  Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, et al.

• 3. Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer. Cancer Chemother Pharmacol 2018;82(4):707-716.

  Nishimura J, Hasegawa J, Kato T, Yoshioka S, Noura S, Kagawa Y, et al.

• 4. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008;455(7214):808-12.

  Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, et al.

• 5. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG). Surg Today 2018;48(1):66-72.

  Miyake Y, Nishimura J, Kato T, Ikeda M, Tsujie M, Hata T, et al.

• 6. (18)F-Fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer. Surg Today 2016;46(10):1152-8.

  Nishimura J, Hasegawa J, Ogawa Y, Miwa H, Uemura M, Haraguchi N, et al.

• 7. microRNA-181a is associated with poor prognosis of colorectal cancer. Oncol Rep 2012;28(6):2221-6.

  Nishimura J, Handa R, Yamamoto H, Tanaka F, Shibata K, Mimori K, et al.

• 8. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol 2017;22(1):88-95.

  Takemoto H, Nishimura J, Komori T, Kim HM, Ota H, Suzuki R, et al.

• 9. The possibility of using fibrin-based collagen as an antibiotic delivery system. Surg Today 2013;43(2):185-90.

  Nishimura J, Nakajima K, Souma Y, Takahashi T, Ikeguchi N, Takenaka R, et al.

• 10. Significance of polypyrimidine tract binding protein 1 expression in colorectal cancer. Mol Cancer Ther 2015. Takahashi H, Nishimura J, Kagawa Y, Kano Y, Takahashi Y, Wu X, et al. Significance of polypyrimidine tract binding protein 1 expression in colorectal cancer. Mol Cancer Ther 2015.

  Takahashi H, Nishimura J, Kagawa Y, Kano Y, Takahashi Y, Wu X, et al.

• 11. Abdominal soft tissue sarcoma: a multicenter retrospective study. Int J Clin Oncol 2010;15(4):399-405.

  Nishimura J, Morii E, Takahashi T, Souma Y, Nakajima K, Doki Y, et al.

• 12. Potent antimycobacterial activity of mouse secretory leukocyte protease inhibitor. J Immunol 2008;180(6):4032-9.

  Nishimura J, Saiga H, Sato S, Okuyama M, Kayama H, Kuwata H, et al.

• 13. Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection. Surg Endosc 2007;21(6):875-8.

  Nishimura J, Nakajima K, Omori T, Takahashi T, Nishitani A, Ito T, et al.

• 14. Advantages of off-pump coronary artery bypass grafting in long-term hemodialysis patients: multicenter analysis. Heart Surg Forum 2004;7(5):E370-3.

  Nishimura J, Akagi H, Sawa Y, Takahashi T, Miyamoto Y, Sakai K, et al.